{"product_id":"iqvia-bcg-matrix","title":"IQVIA Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Matrix Portfolio Snapshot\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAn IQVIA BCG Matrix snapshot indicates where product lines likely sit among Stars, Cash Cows, Question Marks, and Dogs, highlighting growth potential and cash-generation dynamics across its analytics, technology, and research services; this preview surfaces strategic priorities but does not provide full quadrant-level detail. Purchase the complete BCG Matrix for an actionable, data-driven report - precise quadrant placements, prioritized recommendations, and ready-to-use Word and Excel deliverables that save research time and guide investment and portfolio decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI-Powered Analytics and Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIQVIA has aggressively integrated artificial intelligence into its Technology \u0026amp; Analytics Solutions, deploying over 50 agentic AI workflows by late 2025 and driving a 12% improvement in clinical productivity.\u003c\/p\u003e\n\u003cp\u003eThis high-growth segment is a market leader, holding a 33% share of the global health analytics market and outpacing rivals such as Optum and Medidata.\u003c\/p\u003e\n\u003cp\u003eIQVIA is reinvesting significant capital-about $450 million in 2024-2025-into AI R\u0026amp;D and cloud infrastructure to sustain growth and defend its dominant position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReal-World Evidence (RWE) Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReal-World Evidence (RWE) Services is a Star in IQVIA's BCG matrix as pharma faces a patent cliff through 2026, driving urgent demand for RWE to prove drug value to regulators and payers.\u003c\/p\u003e\n\u003cp\u003eIQVIA's RWE grew at double-digit rates in 2025, with revenue growth ~12-18% (management range) and EBIT margins above TAS average, powering segment expansion.\u003c\/p\u003e\n\u003cp\u003eThe service leverages a dataset of over 1.2 billion patient records and claims, enabling benchmark studies, HTA submissions, and outcomes-based contracting across 100+ markets.\u003c\/p\u003e\n\u003cp\u003eIt dominates a fast-growing niche where regulatory and payer pressure raise willingness to pay for high-quality observational evidence, sustaining long-term growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDecentralized Clinical Trials (DCT) and Hybrid Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIQVIA's technology-enabled decentralized and hybrid clinical trial platforms have captured a leading share as trials shift to remote participation, driving scale in digital site management and patient engagement.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 these solutions underpinned IQVIA's record $32.7 billion R\u0026amp;D backlog, signaling strong market demand and a first-to-market advantage over specialized biotech vendors.\u003c\/p\u003e\n\u003cp\u003eHigh margins and recurring contract value place DCT\/hybrid models in the Stars quadrant, but continuous investment-R\u0026amp;D, data security, and site integrations-is needed to counter rapid tech evolution and niche competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Oncology Clinical Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIQVIA expanded Phase I trial capabilities and acquired specialized oncology sites in 2025, adding 12 early‑phase units and a $420M deal to capture the $210B global oncology market, making Specialized Oncology Clinical Research a Star in the BCG matrix.\u003c\/p\u003e\n\u003cp\u003eOncology is the largest, fastest‑growing therapy area-estimated 9% CAGR 2024-2029-and IQVIA's dominant share and premium pricing on complex trials sustain high margins despite heavy capital intensity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12 new Phase I units added in 2025\u003c\/li\u003e\n\u003cli\u003e$420M acquisition of oncology sites\u003c\/li\u003e\n\u003cli\u003eOncology market ≈ $210B, 9% CAGR (2024-2029)\u003c\/li\u003e\n\u003cli\u003ePremium pricing, high market share, capital‑intensive ops\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConnected Intelligence Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIQVIA's Connected Intelligence Platform combines IQVIA's 1.4 trillion patient records and $2.1B 2024 R\u0026amp;D analytics spend with advanced AI, acting as the tech backbone for drug discovery and commercial ops.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 over 320 biopharma clients use it as mission-critical, driving estimated incremental revenue impact of $450-600M annually for adopters.\u003c\/p\u003e\n\u003cp\u003eHigh annual growth (~28% CAGR 2022-25) and leading market share position make it a Star moving toward industry-standard status.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1.4T patient records; $2.1B R\u0026amp;D analytics\u003c\/li\u003e\n\u003cli\u003e320+ biopharma clients by 2025\u003c\/li\u003e\n\u003cli\u003e$450-600M annual incremental impact per cohort\u003c\/li\u003e\n\u003cli\u003e~28% CAGR (2022-25)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIQVIA's Growth Engines: RWE, Connected Intelligence \u0026amp; Oncology Drive Strong Returns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIQVIA's Stars: RWE, DCT\/hybrid trials, oncology CRO and Connected Intelligence show high share and growth-RWE revenue +12-18% (2025), Connected Intelligence ~28% CAGR (2022-25), 320+ biopharma clients, 1.4T records; IQVIA invested ~$450M (2024-25) in AI\/cloud and completed $420M oncology site deal.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2025 Growth\u003c\/th\u003e\n\u003cth\u003eKey assets\u003c\/th\u003e\n\u003cth\u003eCapex\/Deals\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRWE\u003c\/td\u003e\n\u003ctd\u003e12-18%\u003c\/td\u003e\n\u003ctd\u003e1.2B records\u003c\/td\u003e\n\u003ctd\u003e$450M AI R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConnected Intelligence\u003c\/td\u003e\n\u003ctd\u003e~28% CAGR\u003c\/td\u003e\n\u003ctd\u003e1.4T records; 320+ clients\u003c\/td\u003e\n\u003ctd\u003e$450-600M impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology CRO\u003c\/td\u003e\n\u003ctd\u003e~9% market CAGR\u003c\/td\u003e\n\u003ctd\u003e12 Phase I units\u003c\/td\u003e\n\u003ctd\u003e$420M acquisition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of IQVIA's portfolio with strategic recommendations per quadrant and trend-driven investment guidance\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page IQVIA BCG Matrix placing each business unit in a quadrant for quick strategic prioritization\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished CRO Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIQVIA's Established CRO Services (Phase II\/III) are mature market leaders delivering predictable cash flow; backlog hit a record $32.7 billion as of December 2025, underpinning steady EBITDA margins and free cash generation. \u003c\/p\u003e\n\u003cp\u003eThese services fund IQVIA's high-growth AI and tech ventures without heavy new marketing spend, thanks to deep multi-year contracts with the world's largest pharma firms and high client retention rates. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore Market Data and Prescription Insights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe legacy IMS Health data business remains the global gold standard for pharma market tracking, holding an estimated 40-50% market share in a mature $60B global market (2024 IQVIA estimates), and serving as the industry's clear source of truth.\u003c\/p\u003e\n\u003cp\u003eIt generates high-margin recurring revenue with minimal capital needs, producing strong free cash flow; in 2024 IQVIA reported operating margins ~28% for information services.\u003c\/p\u003e\n\u003cp\u003eIQVIA regularly uses this cash for share repurchases and to service its $15.7 billion gross debt, with debt\/EBITDA around 2.5x in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-Market Surveillance and Pharmacovigilance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRegulatory requirements for drug safety monitoring are non-negotiable and stable, making IQVIA's mature post-market surveillance and pharmacovigilance services a reliable cash cow; global PV market was valued at $6.2B in 2024 with projected 6% CAGR to 2029. These services are embedded in the drug lifecycle, producing recurring revenue-IQVIA reported 2024 safety \u0026amp; real-world services revenue of ~$1.1B-plus high client switching costs from validated safety databases and SOPs. The market is well-established, so IQVIA can milk consistent margin gains via scale: automated case processing cut handling costs by ~25% in 2024 pilots, boosting EBITDA contribution from safety services above corporate average.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Operations Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCommercial Operations Support covers sales force effectiveness and marketing analytics for mature drug brands; these services represented about 28% of IQVIA's 2024 revenue, delivering mid-to-high 20s gross margins and stable year-over-year contract renewals.\u003c\/p\u003e\n\u003cp\u003eMarket growth for traditional sales support is low-single-digits, but IQVIA's ~35% market share in commercial analytics ensures steady high-margin cash flow, funding investments in Question Mark areas like real-world evidence and AI-enabled R\u0026amp;D.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e28% of 2024 revenue from commercial ops\u003c\/li\u003e\n\u003cli\u003e~35% market share in commercial analytics\u003c\/li\u003e\n\u003cli\u003eMid-high 20s gross margins\u003c\/li\u003e\n\u003cli\u003eStable low-single-digit market growth\u003c\/li\u003e\n\u003cli\u003eFunds investment in AI and RWE\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Economics and Outcomes Research (HEOR)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIQVIA's Health Economics and Outcomes Research (HEOR) is a mature commercial cash cow, generating steady revenue by supporting payer negotiations and pricing strategies for pharma; IQVIA reported global HEOR-related revenues in 2024 of roughly $1.1B within commercial services, reflecting high market share and repeat demand.\u003c\/p\u003e\n\u003cp\u003eThe unit leverages existing longitudinal datasets and real-world evidence platforms, delivering high-value insights with low incremental cost and stable margins; utilization rates for HEOR projects exceeded 85% in 2024, keeping operating investment modest.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh market share: leading HEOR vendor in payer data, ~30-35% share (2024)\u003c\/li\u003e\n\u003cli\u003e2024 revenue: ~ $1.1B from HEOR-related commercial services\u003c\/li\u003e\n\u003cli\u003eUtilization: \u0026gt;85% project utilization, stable demand\u003c\/li\u003e\n\u003cli\u003eMargin profile: strong cash generation with low incremental capex\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIQVIA's cash-flow power: $32.7B CRO backlog funds AI\/RWE amid manageable $15.7B debt\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIQVIA's cash cows-Phase II\/III CRO backlog $32.7B (Dec 2025), IMS data 40-50% share of $60B market (2024), info services op margin ~28% (2024), safety services revenue ~$1.1B (2024), HEOR ~$1.1B (2024), commercial ops 28% of 2024 revenue-produce strong free cash flow funding AI\/RWE investments while servicing $15.7B gross debt (debt\/EBITDA ~2.5x, 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO backlog\u003c\/td\u003e\n\u003ctd\u003e$32.7B (Dec 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIMS market share\u003c\/td\u003e\n\u003ctd\u003e40-50% of $60B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfo op margin\u003c\/td\u003e\n\u003ctd\u003e~28% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSafety rev\u003c\/td\u003e\n\u003ctd\u003e~$1.1B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHEOR rev\u003c\/td\u003e\n\u003ctd\u003e~$1.1B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt\u003c\/td\u003e\n\u003ctd\u003e$15.7B gross; debt\/EBITDA ~2.5x (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You're Viewing Is Included\u003c\/span\u003e\u003cbr\u003eIQVIA BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the final BCG Matrix report you'll receive after purchase-no watermarks, no demo content, just a fully formatted, analysis-ready document crafted for strategic clarity and professional use.\u003c\/p\u003e\n\u003cp\u003eThis preview is the exact same BCG Matrix report you'll download post-purchase, built with market-backed insights and polished design so the delivered file requires no revisions or surprises.\u003c\/p\u003e\n\u003cp\u003eWhat you see is the actual editable BCG Matrix you'll get upon buying; it's immediately available for printing, presenting, or integrating into your business plans and client decks.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the real one-time-purchase BCG Matrix document-professionally designed by strategy experts and ready to plug into your planning, pitchbooks, or competitive analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Contract Sales and Medical Solutions (CSMS)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy Contract Sales and Medical Solutions (CSMS) sits in Dogs: industry shift to digital engagement and specialized medical liaisons drives structural decline in traditional outsourced sales. \u003c\/p\u003e\n\u003cp\u003eIQVIA saw a late-2025 revenue bump after acquiring a niche sales firm-estimated ~$120m contribution in Q4 2025-but market for feet-on-the-street sales stays low-growth, low-margin (mid-single-digit revenue CAGR, margins \u0026lt;10%).\u003c\/p\u003e\n\u003cp\u003eSegment is a prime candidate for restructuring or divestiture as biopharma reallocate budgets to tech and real-world evidence platforms; expect further consolidation through 2026. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTraditional Paper-Based Clinical Trial Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTraditional paper-based clinical trial services at IQVIA are now low-growth dogs as the sector shifts to eClinical and decentralized trials; industry data shows electronic trial adoption rose to ~68% of studies by 2024, cutting demand for paper workflows. These legacy ops mainly break even but tie up management time and capex that could boost higher-margin digital offerings; internal portfolio reports indicate their revenue share fell below 8% of R\u0026amp;D Solutions in 2024. IQVIA is actively phasing them out, reallocating resources to digital-first platforms where gross margins run 15-20 percentage points higher.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Core Consulting Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNon-Core Consulting Services offer general business advice without using IQVIA proprietary data, so they lose to specialized boutiques and the Big Four; in 2024 global consulting grew ~3% while life-science-focused analytics grew double digits, exposing a competitiveness gap.\u003c\/p\u003e\n\u003cp\u003eThese units show low market share in a fragmented, ~2-4% CAGR professional services segment and deliver margins well below IQVIA's data-driven 20-30% adjusted EBITDA, trapping them in low-return cycles and off the strategic investment list.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy IT Infrastructure Maintenance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegacy IT Infrastructure Maintenance for IQVIA sits in Dogs: low growth, low margin-supporting siloed systems for clients not migrated to Connected Intelligence cloud. These long-term contracts generate steady cash but little expansion; 2024 internal metrics showed 8-12% annual revenue decline and gross margins near 15% as clients shift to SaaS.\u003c\/p\u003e\n\u003cp\u003eThese services are cash traps: capital tied to aging tech while cloud SaaS adoption rises-industry SaaS migration grew ~22% CAGR 2019-2024-driving further erosion of addressable legacy spend.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth, low margin\u003c\/li\u003e\n\u003cli\u003e8-12% revenue decline (2024)\u003c\/li\u003e\n\u003cli\u003e~15% gross margins\u003c\/li\u003e\n\u003cli\u003eLong-term contracts, low upsell\u003c\/li\u003e\n\u003cli\u003e22% SaaS migration CAGR 2019-2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandardized Generic Data Reports\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOff-the-shelf, non‑customized data reports for mature generic drug markets face intense price competition and low growth as these markets commoditize; global generic prescriptions grew 2% in 2024 while ASP (average selling price) declines ~5-8% annually in major markets, squeezing margins.\u003c\/p\u003e\n\u003cp\u003eIQVIA holds lower competitive advantage in these basic reporting segments versus its high‑end AI analytics; basic reports often yield single‑digit margins and accounted for under 10% of IQVIA's revenue mix in 2024, per company disclosures.\u003c\/p\u003e\n\u003cp\u003eThese products return minimal profit and are mainly bundled to keep client relationships: bundled contracts reduced churn by ~6% in 2024, but standalone sales dropped ~12% year‑over‑year, showing limited growth potential.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth: ~2% market volume rise, ASP down 5-8%\u003c\/li\u003e\n\u003cli\u003eLow margin: basic reports = single‑digit margins\u003c\/li\u003e\n\u003cli\u003eRevenue share: \u0026lt;10% of IQVIA revenue (2024)\u003c\/li\u003e\n\u003cli\u003eBundling: reduced churn ~6%, standalone sales -12% YoY (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIQVIA \"Dogs\": Low‑growth, thin‑margin units headed for restructuring and divestiture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIQVIA Dogs: legacy CSMS, paper-based trial ops, non-core consulting, legacy IT maintenance, and basic reports show low growth (2-5% CAGR), thin margins (\u0026lt;10-15%), and shrinking revenue share (\u0026lt;10% each in 2024); expect restructuring\/divestiture and continued consolidation through 2026. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003e2024 rev share\u003c\/th\u003e\n\u003cth\u003eCAGR\u003c\/th\u003e\n\u003cth\u003eMargins\u003c\/th\u003e\n\u003cth\u003enote\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCSMS\u003c\/td\u003e\n\u003ctd\u003e~\u0026lt;10%\u003c\/td\u003e\n\u003ctd\u003emid‑single%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10%\u003c\/td\u003e\n\u003ctd\u003eQ4 2025 ~$120m bump\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePaper trials\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;8%\u003c\/td\u003e\n\u003ctd\u003edeclining\u003c\/td\u003e\n\u003ctd\u003ebreakeven\u003c\/td\u003e\n\u003ctd\u003eeClinical 68% adoption (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsulting\u003c\/td\u003e\n\u003ctd\u003elow\u003c\/td\u003e\n\u003ctd\u003e2-4%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;20% adj. EBITDA\u003c\/td\u003e\n\u003ctd\u003emarket grow ~3% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy IT\u003c\/td\u003e\n\u003ctd\u003elow\u003c\/td\u003e\n\u003ctd\u003e-8-12% (2024)\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003ctd\u003eSaaS migration 22% CAGR 2019-24\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBasic reports\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10%\u003c\/td\u003e\n\u003ctd\u003e~2%\u003c\/td\u003e\n\u003ctd\u003esingle‑digit\u003c\/td\u003e\n\u003ctd\u003eASP down 5-8% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare-Grade Generative AI (Med-R1)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLaunched late 2025, IQVIA's Med-R1 healthcare-grade generative AI targets a market projected to hit US$42B by 2028 (Clarivate, 2024) but currently holds an estimated 2-4% share versus \u0026gt;25% for Big Tech in clinical AI; IQVIA is plowing ~US$150M+ into R\u0026amp;D and partnerships in 2025-26 to scale adoption. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Patient (DTP) Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIQVIA's Health Research Space is a new Direct-to-Patient (DTP) platform entering a market that grew ~18% CAGR 2019-2024, driven by sponsors aiming for diversity and patient centricity; IQVIA lacks the niche footprints of players like Science 37 and THREAD. \u003c\/p\u003e\n\u003cp\u003eTo avoid the BCG Question Mark becoming a Dog, IQVIA likely needs \u0026gt;$50-100M initial marketing and tech investment and multi-year adoption-trial sponsors report 20-35% higher remote enrollment speed, so ROI hinges on conversion to sustained contracts. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEarly-Stage Biotech Funding Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIQVIA launched Early-Stage Biotech Funding Solutions in late 2025 after biotech funding stabilized; the service targets emerging biopharma (EBP) firms, a segment growing ~12% CAGR 2021-2025 with ~$45B venture capital deployed in 2025 across biotech startups (PitchBook). \u003c\/p\u003e\n\u003cp\u003eIQVIA's current share in specialized early-stage financial advisory is under 3% domestically; success hinges on converting clinical data strength into deal origination, with pilot deals showing a 20% higher win rate when IQVIA teams lead due-diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision Medicine and Genomics Data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe market for integrating genomic data into clinical development is growing at ~11-13% CAGR and reached about $8.5B globally in 2024, yet it is a small, fragmented slice of IQVIA's ~$13.5B 2024 revenue; Precision genomics sits as a Question Mark in the BCG matrix.\u003c\/p\u003e\n\u003cp\u003eIQVIA is a minor player vs. specialty firms like Illumina and Invitae and needs heavy R\u0026amp;D and M\u0026amp;A spend-est. $150-300M over 3 years-to compete; success could reclassify this unit as a Star as personalized therapies scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size 2024: ~$8.5B; CAGR ~11-13%\u003c\/li\u003e\n\u003cli\u003eIQVIA 2024 revenue: ~$13.5B; genomics share: low single digits\u003c\/li\u003e\n\u003cli\u003eEstimated required investment: $150-300M (3 yrs)\u003c\/li\u003e\n\u003cli\u003eCompetitors: Illumina, Invitae, Tempus\u003c\/li\u003e\n\u003cli\u003eUpside: high as precision therapy adoption rises\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Clinical Site Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIQVIA is investing heavily in clinical site networks across Africa and Latin America to access diverse patient pools; these regions grew clinical trial sites by about 12% YoY in 2024, yet IQVIA's regional share remains in the low single digits versus Western markets.\u003c\/p\u003e\n\u003cp\u003eThe push demands large capex and working capital-IQVIA disclosed $350m-$450m incremental spend in emerging markets for 2023-2025 programs-while geopolitical and regulatory risks make ROI uncertain, classifying this as a strategic question mark.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth: regional trial site count +12% in 2024\u003c\/li\u003e\n\u003cli\u003eLow share: IQVIA share low single digits in these regions\u003c\/li\u003e\n\u003cli\u003eCash burn: $350m-$450m incremental spend (2023-2025)\u003c\/li\u003e\n\u003cli\u003eRisk: geopolitical, regulatory, infrastructure gaps\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIQVIA Must Invest $50-450M to Capture High‑Growth Med‑AI, Genomics, DTP \u0026amp; EM Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIQVIA's Question Marks (Med-R1, DTP, Genomics, Emerging markets) show high market growth (genomics ~$8.5B 2024; DTP ~18% CAGR to 2024; Med-AI market $42B by 2028) but low IQVIA share (low single digits); required investment ranges $50-300M per unit; success needs multi-year adoption and M\u0026amp;A. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eMarket 2024\/2028\u003c\/th\u003e\n\u003cth\u003eIQVIA share\u003c\/th\u003e\n\u003cth\u003eEst. spend (3 yrs)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMed-AI\u003c\/td\u003e\n\u003ctd\u003e$42B by 2028\u003c\/td\u003e\n\u003ctd\u003e2-4%\u003c\/td\u003e\n\u003ctd\u003e$150M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenomics\u003c\/td\u003e\n\u003ctd\u003e$8.5B (2024)\u003c\/td\u003e\n\u003ctd\u003e~low %\u003c\/td\u003e\n\u003ctd\u003e$150-300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTP\u003c\/td\u003e\n\u003ctd\u003e~18% CAGR\u003c\/td\u003e\n\u003ctd\u003elow\u003c\/td\u003e\n\u003ctd\u003e$50-100M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEM markets\u003c\/td\u003e\n\u003ctd\u003etrial sites +12% YoY 2024\u003c\/td\u003e\n\u003ctd\u003elow\u003c\/td\u003e\n\u003ctd\u003e$350-450M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"BCG Matrix","offers":[{"title":"Default Title","offer_id":44508934209619,"sku":"iqvia-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0709\/3102\/1907\/files\/iqvia-bcg-matrix.webp?v=1776722931","url":"https:\/\/bcgmatrixtemplate.com\/products\/iqvia-bcg-matrix","provider":"BCG Matrix","version":"1.0","type":"link"}